Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. CLOV
CLOV logo

CLOV Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
5.205
Open
5.020
VWAP
5.06
Vol
5.71M
Mkt Cap
2.63B
Low
4.960
Amount
28.88M
EV/EBITDA(TTM)
--
Total Shares
526.68M
EV
2.46B
EV/OCF(TTM)
42.99
P/S(TTM)
1.19
Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states.
Show More

Events Timeline

(ET)
2026-06-10
16:30:00
US Stocks Drop Sharply Amid Renewed US-Iran Tensions
select
2026-06-10
12:10:00
Major U.S. Averages Decline Amid Escalating Geopolitical Tensions
select
2026-06-10
12:10:00
Clover Health Stock Price Rises
select
2026-03-04 (ET)
2026-03-04
08:40:00
Clover Health Partners with CMS for Data Interoperability
select

News

Newsfilter
7.5
07-07Newsfilter
Counterpart Health Releases Whitepaper on Care Transitions
  • Clinical Performance Improvement: The whitepaper reveals that primary care physicians using Counterpart Assistant outperformed on HEDIS transitions of care metrics, particularly in inpatient admission notifications and discharge information receipt, demonstrating the platform's effectiveness in enhancing patient care quality.
  • Efficiency in Information Retrieval: Patients attributed to CA-enabled PCPs experienced a 33% increase in discharge information receipt and an 11% rise in medication reconciliation rates, which not only enhances patient safety but also improves overall healthcare service efficiency.
  • Timeliness of ED Follow-Up Enhanced: CA-supported PCPs showed a 9% improvement on the HEDIS FMC measure for high-risk patients, indicating the tool's potential in reducing care interruptions and enhancing continuity of care for patients post-discharge.
  • Strategic Implications Significant: Counterpart Health's analysis indicates that the application of CA can lower acute care utilization while providing timely information support, enabling primary care providers to effectively intervene during critical post-discharge periods, thereby reducing overall healthcare costs.
Fool
5.0
07-07Fool
Clover Health CEO Sells 313,476 Shares for $1.67 Million
  • Transaction Overview: Clover Health CEO Andrew Toy sold 313,476 shares of common stock on July 1, 2026, for approximately $1.67 million, based on a reported price of $5.32 per share, demonstrating the company's liquidity management capabilities at a high valuation.
  • Ownership Change Analysis: Following this transaction, Toy's direct holdings decreased by 3.16%, retaining 9,609,825 shares valued at $51.8 million, indicating his continued confidence in the company's long-term prospects despite the sale.
  • Market Reaction and Investor Confidence: Although the sale occurred shortly after the stock hit a multi-year high of $5.59, it was a non-discretionary transaction to cover tax obligations, alleviating investor concerns and reinforcing alignment between management and shareholder interests.
  • Business Growth Outlook: Clover Health reported a 51% year-over-year increase in Medicare Advantage memberships in Q1 2026, driving a 62% year-over-year revenue growth to $749.2 million, with management forecasting full-year sales between $2.8 billion and $2.9 billion, significantly higher than 2025's $1.9 billion, reflecting strong market demand and growth potential.
NASDAQ.COM
5.0
07-07NASDAQ.COM
Clover Health CEO Andrew Toy Sells 313,476 Shares for $1.67 Million
  • Executive Share Sale: Clover Health CEO Andrew Toy sold 313,476 shares of common stock on July 1, 2026, for approximately $1.67 million, representing 3.16% of his direct holdings, reducing his ownership to 9,609,825 shares, indicating a non-discretionary sale to meet tax obligations.
  • Stock Performance Context: This sale occurred shortly after the company's shares reached a multi-year high of $5.59 on June 29, yet investor sentiment remained stable as the transaction was necessary for tax withholding related to RSU vesting, aligning Toy's interests with those of shareholders.
  • Strong Membership Growth: Clover Health reported a remarkable 51% year-over-year increase in Medicare Advantage memberships in Q1 2026, contributing to a 62% year-over-year revenue growth to $749.2 million, showcasing the company's robust performance in the U.S. Medicare market.
  • Full-Year Sales Forecast: Clover Health's management forecasts full-year sales between $2.8 billion and $2.9 billion for 2026, a significant increase from $1.9 billion in 2025, reflecting the company's competitive positioning and potential for future growth.
Yahoo Finance
5.0
07-07Yahoo Finance
Clover Health CEO Sells $1.7 Million in Shares: Investor Implications
  • Transaction Overview: Clover Health CEO Andrew Toy sold 313,476 shares of common stock on July 1, 2026, for approximately $1.67 million, resulting in a 3.16% decrease in his direct holdings, yet he retains 9,609,825 shares valued at $51.8 million.
  • Tax Obligation Driven: This stock sale was executed to cover tax obligations related to the vesting of restricted stock units (RSUs), indicating no negative sentiment towards the company's future, as Toy maintains about 96.8% of his pre-sale direct position, allowing for substantial future selling capacity.
  • Strong Performance Growth: Clover Health reported a 51% year-over-year increase in Medicare Advantage memberships in Q1 2026, contributing to a 62% year-over-year revenue growth to $749.2 million, with management forecasting full-year sales between $2.8 billion and $2.9 billion, a significant rise from $1.9 billion in 2025.
  • Positive Market Reaction: Although Toy's stock sale occurred shortly after shares peaked at $5.59, the non-discretionary nature of the transaction alleviates investor concerns, allowing them to focus on Clover Health's ongoing growth potential in the Medicare market.
Fool
5.0
06-27Fool
Clover Health Board Member Sells 67,160 Shares
  • Transaction Overview: On May 18, 2026, Dr. Carladenise Armbrister Edwards, a member of Clover Health's Board of Directors, reported a direct sale of 67,160 shares, valued at approximately $230,000, indicating a reduction in her stake in the company.
  • Holding Changes: This transaction reduced Edwards' direct holdings by 19.05%, from 352,592 shares to 285,432 shares, reflecting a decrease in available holdings that may stem from routine portfolio management practices.
  • Market Performance Impact: The sale price of around $3.42 per share was slightly below the market close, occurring during a period when the stock's one-year total return was 8.23%, suggesting that muted market performance may have influenced her decision to sell.
  • Company Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with a 51% rise in Medicare Advantage memberships, transitioning from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million this year, showcasing strong performance in the healthcare insurance market.
NASDAQ.COM
5.0
06-27NASDAQ.COM
Clover Health Director Sells Shares Amid Price Surge
  • Share Sale Details: Director Carladenise Edwards sold 67,160 shares on May 18, 2026, at a weighted average price of approximately $3.42 per share, totaling around $230,000, which represented 19% of her direct holdings, reducing her ownership from 352,592 to 285,432 shares.
  • Market Reaction Analysis: This sale occurred during a period of rising stock prices following Clover Health's excellent first-quarter earnings report, with shares reaching a 52-week high of $5.49 on June 26, indicating strong market confidence in the company's future growth prospects.
  • Financial Performance Highlights: Clover Health reported a 62% year-over-year revenue increase in Q1 2026, reaching $749.2 million, with Medicare Advantage memberships growing by 51%, successfully turning around from a net loss of $1.3 million in Q1 2025 to a net income of $27.3 million, showcasing robust business recovery.
  • Investor Advisory: Despite Clover Health's impressive performance, the Motley Fool analyst team did not include it in their current list of top investment stocks, advising investors to exercise caution and consider overall market performance and potential risks when making investment decisions.
Wall Street analysts forecast CLOV stock price to rise
2 Analyst Rating
Wall Street analysts forecast CLOV stock price to rise
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 0.000
sliders
Low
3.00
Averages
3.35
High
3.70
Current: 0.000
sliders
Low
3.00
Averages
3.35
High
3.70
UBS
Jonathan Yong
Neutral
maintain
AI Analysis
2026-06-11
Reason
UBS
Jonathan Yong
Price Target
AI Analysis
2026-06-11
maintain
Neutral
Reason
UBS analyst Jonathan Yong raised the firm's price target on Clover Health to $4.75 from $2.75 and keeps a Neutral rating on the shares.
Canaccord
Richard Close
Buy
upgrade
2026-06-04
Reason
Canaccord
Richard Close
Price Target
2026-06-04
upgrade
Buy
Reason
Canaccord analyst Richard Close raised the firm's price target on Clover Health to $4.20 from $3.20 and keeps a Buy rating on the shares. The firm said its 2026 thesis is playing out as managed care rising tide is liftng both employer and payer digital health boats as strong performance in April and May has led to decent appreciation.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for CLOV
Unlock Now

Valuation Metrics

The current forward P/E ratio for Clover Health Investments Corp (CLOV.O) is 81.97, compared to its 5-year average forward P/E of -0.97. For a more detailed relative valuation and DCF analysis to assess Clover Health Investments Corp's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-0.97
Current PE
81.97
Overvalued PE
32.25
Undervalued PE
-34.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
9.56
Current EV/EBITDA
21.11
Overvalued EV/EBITDA
29.10
Undervalued EV/EBITDA
-9.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
0.59
Current PS
0.83
Overvalued PS
0.98
Undervalued PS
0.20

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

need penny stocks up 30 rsi
Intellectia · 26 candidates
Price: <= $5.00Rsi Category: overbought
Ticker
Name
Market Cap$
top bottom
APWC logo
APWC
Asia Pacific Wire & Cable Corporation Ltd
82.05M
EXFY logo
EXFY
Expensify Inc
150.44M
SOWG logo
SOWG
Sow Good Inc
77.86M
CLWT logo
CLWT
Euro Tech Holdings Company Ltd
14.16M
WPRT logo
WPRT
Westport Fuel Systems Inc
39.31M
GEG logo
GEG
Great Elm Group Inc
86.55M
strong penny stocks
Intellectia · 16 candidates
Price: <= $5.00Relative Vol: >= 1.50Beta: HighRiskMoving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
DTSS logo
DTSS
Datasea Intelligent Technology Ltd
10.45M
VRA logo
VRA
Vera Bradley Inc
98.40M
SXTC logo
SXTC
China SXT Pharmaceuticals Inc
86.37M
NXGL logo
NXGL
Nexgel Inc
5.44M
NRDY logo
NRDY
Nerdy Inc
182.31M
NVX logo
NVX
NOVONIX Ltd
146.58M
best penny stock today
Intellectia · 60 candidates
Price: <= $5.00Market Cap Category: small, mid, large, megaPrice Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20Week Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
ALVO logo
ALVO
Alvotech SA
979.83M
EVH logo
EVH
Evolent Health Inc
425.18M
IOVA logo
IOVA
Iovance Biotherapeutics Inc
1.69B
ANGX logo
ANGX
Angel Studios Inc
497.72M
BTQ logo
BTQ
BTQ Technologies Corp
599.37M
CURR logo
CURR
CURRENC Group Inc
349.20M
list penny stocks
Intellectia · 67 candidates
Market Cap: 100.00M - 1000.00MRegion: USPrice: $1.00 - $5.00Quarter Revenue Yoy Growth: >= 10.0%List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
BTBT logo
BTBT
Bit Digital Inc
466.09M
VERI logo
VERI
Veritone Inc
239.61M
HIVE logo
HIVE
HIVE Digital Technologies Ltd
488.79M
PACB logo
PACB
Pacific Biosciences of California Inc
407.70M
MNKD logo
MNKD
MannKind Corp
708.63M
BLDP logo
BLDP
Ballard Power Systems Inc
737.24M
less than 3 usd
Intellectia · 1118 candidates
Price: <= $3.00
Ticker
Name
Market Cap$
top bottom
ABEV logo
ABEV
Ambev SA
41.38B
WIT logo
WIT
Wipro Ltd
27.24B
CIG.C logo
CIG.C
Companhia Energetica De Minas Gerais-CEMIG
7.70B
CIG logo
CIG
Energy of Minas Gerais Co
5.98B
FUBO logo
FUBO
FuboTV Inc
3.33B
PLUG logo
PLUG
Plug Power Inc
3.09B
best $5 stocks to buy now
Intellectia · 71 candidates
Market Cap: >= 500.00MPrice: <= $5.00Weekly Average Turnover: >= 1,000,000Month Price Change Pct: >= $0.00
Ticker
Name
Market Cap$
top bottom
UP logo
UP
Wheels Up Experience Inc
624.57M
ASST logo
ASST
Strive Inc
1.11B
KOS logo
KOS
Kosmos Energy Ltd
617.04M
OPK logo
OPK
OPKO Health Inc
1.06B
LXRX logo
LXRX
Lexicon Pharmaceuticals Inc
566.90M
OLPX logo
OLPX
Olaplex Holdings Inc
1.06B
to increase in price
Intellectia · 25 candidates
Market Cap: >= 500.00MPrice: <= $5.00Analyst Consensus: Moderate Buy, Strong BuyMoving Average Relationship: PriceAboveMA20Annual Eps Yoy Growth: >= 10.0%
Ticker
Name
Market Cap$
top bottom
AUR logo
AUR
Aurora Innovation Inc
9.02B
BTE logo
BTE
Baytex Energy Corp
2.64B
NWL logo
NWL
Newell Brands Inc
1.79B
CLOV logo
CLOV
Clover Health Investments Corp
1.35B
BORR logo
BORR
Borr Drilling Ltd
1.34B
SANA logo
SANA
Sana Biotechnology Inc
1.27B
penny stocks on the move today
Intellectia · 52 candidates
Price: <= $5.00Price Change Pct: >= $1.00Relative Vol: >= 1Beta: HighRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
RIG logo
RIG
Transocean Ltd
5.10B
DNN logo
DNN
Denison Mines Corp
3.36B
RXRX logo
RXRX
Recursion Pharmaceuticals Inc
2.40B
TV logo
TV
Grupo Televisa SAB
1.74B
CLOV logo
CLOV
Clover Health Investments Corp
1.35B
BAK logo
BAK
Braskem SA
1.31B
I want to buy penny stock
Intellectia · 182 candidates
Market Cap: <= 2.00BPrice: <= $5.00Beta: HighRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True
Ticker
Name
Market Cap$
top bottom
MQ logo
MQ
Marqeta Inc
1.94B
CLVT logo
CLVT
Clarivate PLC
1.86B
NWL logo
NWL
Newell Brands Inc
1.79B
TV logo
TV
Grupo Televisa SAB
1.74B
BITF logo
BITF
Bitfarms Ltd
1.61B
PGEN logo
PGEN
Precigen Inc
1.58B
Penny stock that will double tomorrow
Intellectia · 129 candidates
Price: <= $5.00Price Change Pct: >= $1.00Relative Vol: >= 1Weekly Average Turnover: >= 1,000,000Option Unusual Activity: False
Ticker
Name
Market Cap$
top bottom
ABEV logo
ABEV
Ambev SA
41.38B
BBD logo
BBD
Banco Bradesco SA
39.45B
GGB logo
GGB
Gerdau SA
8.43B
CIG logo
CIG
Energy of Minas Gerais Co
5.98B
RIG logo
RIG
Transocean Ltd
5.10B
UGP logo
UGP
Ultrapar Participacoes SA
4.69B

Whales Holding CLOV

G
GMT Capital Corp.
Holding
CLOV
+9.00%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Clover Health Investments Corp (CLOV) stock price today?

The current price of CLOV is 5 USD — it has decreased -1.19

What is Clover Health Investments Corp (CLOV)'s business?

Clover Health Investments, Corp. is a physician enablement technology company. The Company is focused on bringing access to healthcare to everyone on Medicare. This includes a focus on seniors, who have historically lacked access to affordable healthcare. Its software platform, Clover Assistant, is a technology platform that empowers providers to deliver intuitive data-driven, personalized care to help physicians detect, identify, and manage diseases earlier. This physician-enablement platform is designed to synthesize comprehensive, longitudinal sets of data to generate provider-focused machine learning, artificial intelligence and rules-based insights, and to drive action by surfacing the relevant, personalized information about each patient to his or her provider. The Company, through its Insurance segment, provides Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans to Medicare Advantage (MA) members in several states.

What is the price predicton of CLOV Stock?

Wall Street analysts forecast CLOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLOV is3.35 USD with a low forecast of 3.00 USD and a high forecast of 3.70 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Clover Health Investments Corp (CLOV)'s revenue for the last quarter?

Clover Health Investments Corp revenue for the last quarter amounts to 749.19M USD, increased 62.05

What is Clover Health Investments Corp (CLOV)'s earnings per share (EPS) for the last quarter?

Clover Health Investments Corp. EPS for the last quarter amounts to 0.05 USD, decreased

How many employees does Clover Health Investments Corp (CLOV). have?

Clover Health Investments Corp (CLOV) has 724 emplpoyees as of July 08 2026.

What is Clover Health Investments Corp (CLOV) market cap?

Today CLOV has the market capitalization of 2.63B USD.